Diploma (LON:DPLM) Shares Pass Above Two Hundred Day Moving Average of $3,349.58

Diploma PLC (LON:DPLM - Get Free Report) shares crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 3,349.58 ($42.07) and traded as high as GBX 3,652 ($45.87). Diploma shares last traded at GBX 3,628 ($45.57), with a volume of 279,461 shares traded.

Analyst Upgrades and Downgrades

A number of analysts have commented on DPLM shares. Berenberg Bank increased their price objective on shares of Diploma from GBX 3,800 ($47.73) to GBX 4,400 ($55.27) and gave the company a "buy" rating in a report on Thursday, March 28th. Shore Capital reaffirmed a "buy" rating on shares of Diploma in a report on Wednesday, March 27th.

Read Our Latest Stock Report on Diploma

Diploma Price Performance

The stock has a market cap of £4.85 billion, a price-to-earnings ratio of 4,020.00, a P/E/G ratio of 2.82 and a beta of 0.73. The company has a current ratio of 2.06, a quick ratio of 0.80 and a debt-to-equity ratio of 44.05. The company's fifty day moving average is GBX 3,511.04 and its two-hundred day moving average is GBX 3,349.58.

Diploma Increases Dividend

The company also recently disclosed a dividend, which was paid on Friday, February 2nd. Stockholders of record on Thursday, January 18th were paid a GBX 40 ($0.50) dividend. The ex-dividend date was Thursday, January 18th. This is a boost from Diploma's previous dividend of $16.50. This represents a dividend yield of 1.32%. Diploma's payout ratio is presently 6,333.33%.


Diploma Company Profile

(Get Free Report)

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.

Read More

→ Obama’s Forever Term [exposed] (From Porter & Company) (Ad)

Should you invest $1,000 in Diploma right now?

Before you consider Diploma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.

While Diploma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Featured Articles and Offers

Search Headlines: